Oncología Hepática
Humanitas University
Rozzano, ItaliaPublications in collaboration with researchers from Humanitas University (12)
2024
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
Combination immunotherapy for hepatocellular carcinoma
Journal of Hepatology, Vol. 79, Núm. 2, pp. 506-515
-
Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516
2022
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
-
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Journal of Hepatology, Vol. 75, Núm. 4, pp. 960-974
2020
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
-
Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus
HPB, Vol. 22, Núm. 10, pp. 1429-1441